Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Neoleukin Therapeutics, Inc. | d882730dex322.htm |
| EX-32.1 - EX-32.1 - Neoleukin Therapeutics, Inc. | d882730dex321.htm |
| EX-31.2 - EX-31.2 - Neoleukin Therapeutics, Inc. | d882730dex312.htm |
| EX-31.1 - EX-31.1 - Neoleukin Therapeutics, Inc. | d882730dex311.htm |
| EX-21.1 - EX-21.1 - Neoleukin Therapeutics, Inc. | d882730dex211.htm |
| EX-10.8 - EX-10.8 - Neoleukin Therapeutics, Inc. | d882730dex108.htm |
| EX-4.3 - EX-4.3 - Neoleukin Therapeutics, Inc. | d882730dex43.htm |
| 10-K - 10-K - Neoleukin Therapeutics, Inc. | d882730d10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statements Nos.333-194490, 333-203179, 333-210172, 333-216572, 333-223589 and 333-234734 on Form S-8 and Nos. 333-215457 and 333-223584 on Form S-3 of our report dated March 12, 2020, relating to the financial statements of Neoleukin Therapeutics, Inc. appearing in this Annual Report on Form 10-K of Neoleukin Therapeutics, Inc. for the year ended December 31, 2019.
/s/ Deloitte LLP
Chartered Professional Accountants
Vancouver, Canada
March 12, 2020
123